COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more
COSCIENS Biopharma Inc. (CSCI) - Total Liabilities
Latest total liabilities as of June 2025: $20.46 Million USD
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has total liabilities worth $20.46 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
COSCIENS Biopharma Inc. - Total Liabilities Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
COSCIENS Biopharma Inc. Competitors by Total Liabilities
The table below lists competitors of COSCIENS Biopharma Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inception Growth Acquisition Ltd
NASDAQ:IGTA
|
USA | $7.15 Million |
|
High Peak Royalties Ltd
AU:HPR
|
Australia | AU$1.21 Million |
|
Salutica Bhd
KLSE:0183
|
Malaysia | RM16.82 Million |
|
Gunpoint Exploration Ltd
PINK:CJIMF
|
USA | $335.00K |
|
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
|
Turkey | TL419.20 Million |
|
Desane Group Holdings Ltd
AU:DGH
|
Australia | AU$35.11 Million |
|
Corre Energy BV
IR:CORRE
|
Ireland | €31.62 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down COSCIENS Biopharma Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COSCIENS Biopharma Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual total liabilities of COSCIENS Biopharma Inc. from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $21.91 Million | +708.45% |
| 2023-12-31 | $2.71 Million | -32.46% |
| 2022-12-31 | $4.01 Million | +53.58% |
| 2021-12-31 | $2.61 Million | -32.20% |
| 2020-12-31 | $3.85 Million | +1.55% |
| 2019-12-31 | $3.79 Million | +145.00% |
| 2018-12-31 | $1.55 Million | -63.00% |
| 2017-12-31 | $4.19 Million | +40.98% |
| 2016-12-31 | $2.97 Million | -47.36% |
| 2015-12-31 | $5.64 Million | +17.10% |
| 2014-12-31 | $4.82 Million | +5.69% |
| 2013-12-31 | $4.56 Million | +17.08% |
| 2012-12-31 | $3.89 Million | +8.79% |
| 2011-12-31 | $3.58 Million | +2.98% |
| 2010-12-31 | $3.47 Million | -12.20% |
| 2009-12-31 | $3.96 Million | -7.72% |
| 2008-12-31 | $4.29 Million | +39.96% |
| 2007-12-31 | $3.06 Million | +103.01% |
| 2006-12-31 | $1.51 Million | -10.47% |
| 2005-12-31 | $1.69 Million | +26.35% |
| 2004-12-31 | $1.33 Million | +98.15% |
| 2003-12-31 | $673.27K | -18.36% |
| 2002-12-31 | $824.69K | -13.09% |
| 2001-12-31 | $948.90K | -47.01% |
| 2000-12-31 | $1.79 Million | +18.35% |
| 1999-12-31 | $1.51 Million | +45.50% |
| 1998-12-31 | $1.04 Million | -59.78% |
| 1997-12-31 | $2.59 Million | -66.57% |
| 1996-12-31 | $7.73 Million | -- |